Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV 591 RAPIDVAX
PACTR202311679101744Phase 1Not yet recruiting
- Sponsor
- Office of the Surgeon General
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 1 trial of RapidVax and Placebo-COD Research Private Ltd in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Office of the Surgeon General. Primary endpoints: Solicited local and systemic adverse events, Unsolicited adverse events and 2 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
RapidVaxPlacebo-COD Research Private Ltd
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202311679101744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202311679101744.